Formulation of a personalised fetal and obstetric risk prediction score based on maternal thyroid function. (Q3155443): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Removed claim: summary (P836): Thyroid function parameters, especially in pregnant women, are subject to significant intra- and intersubjective variability that hinders their clinical interpretation and standardisation of diagnostic and therapeutic criteria. Objective: Generate a personalised and predictive score of obstetric-perinatal complications and concentration of fetal neurodevelopment biomarkers based on the determination of maternal first trimester TSH corrected...)
(‎Created claim: summary (P836): Thyroid function parameters, especially in pregnant women, are subject to significant intra- and intersubjective variability that hinders their clinical interpretation and standardisation of diagnostic and therapeutic criteria. Objective: Generate a personalised and predictive score of obstetric-perinatal complications and concentration of fetal neurodevelopment biomarkers based on the determination of maternal first trimester TSH corrected by...)
Property / summary
 
Thyroid function parameters, especially in pregnant women, are subject to significant intra- and intersubjective variability that hinders their clinical interpretation and standardisation of diagnostic and therapeutic criteria. Objective: Generate a personalised and predictive score of obstetric-perinatal complications and concentration of fetal neurodevelopment biomarkers based on the determination of maternal first trimester TSH corrected by the most relevant factors that determine the variability of this parameter. Methodology: (a): a1) TSH study in the first trimester based on cluster sampling in 400 pregnant women and genesis of a nomogram using multiple regression analysis; analysis of internal/external validity in the determination of free T4 during gestation. b) Fetal cord blood measurement of neurodevelopment biomarkers (brain-derived neurotrophic factor (BDNF), lysophosphatidic acid (LPA), growth-derived neurotrophic factor (GDNF)); evaluation of obstetric or perinatal complications. Given that there is no consensus among the different scientific societies on the need for universal screening of thyroid dysfunction during the first trimester and that a universally accepted thyrotropin cut-off point has not been established to initiate treatment with thyroxine in pregnant women, the results of the project will establish a personalised TSH cut-off point that allows therapeutic decision-making. (English)
Property / summary: Thyroid function parameters, especially in pregnant women, are subject to significant intra- and intersubjective variability that hinders their clinical interpretation and standardisation of diagnostic and therapeutic criteria. Objective: Generate a personalised and predictive score of obstetric-perinatal complications and concentration of fetal neurodevelopment biomarkers based on the determination of maternal first trimester TSH corrected by the most relevant factors that determine the variability of this parameter. Methodology: (a): a1) TSH study in the first trimester based on cluster sampling in 400 pregnant women and genesis of a nomogram using multiple regression analysis; analysis of internal/external validity in the determination of free T4 during gestation. b) Fetal cord blood measurement of neurodevelopment biomarkers (brain-derived neurotrophic factor (BDNF), lysophosphatidic acid (LPA), growth-derived neurotrophic factor (GDNF)); evaluation of obstetric or perinatal complications. Given that there is no consensus among the different scientific societies on the need for universal screening of thyroid dysfunction during the first trimester and that a universally accepted thyrotropin cut-off point has not been established to initiate treatment with thyroxine in pregnant women, the results of the project will establish a personalised TSH cut-off point that allows therapeutic decision-making. (English) / rank
 
Normal rank
Property / summary: Thyroid function parameters, especially in pregnant women, are subject to significant intra- and intersubjective variability that hinders their clinical interpretation and standardisation of diagnostic and therapeutic criteria. Objective: Generate a personalised and predictive score of obstetric-perinatal complications and concentration of fetal neurodevelopment biomarkers based on the determination of maternal first trimester TSH corrected by the most relevant factors that determine the variability of this parameter. Methodology: (a): a1) TSH study in the first trimester based on cluster sampling in 400 pregnant women and genesis of a nomogram using multiple regression analysis; analysis of internal/external validity in the determination of free T4 during gestation. b) Fetal cord blood measurement of neurodevelopment biomarkers (brain-derived neurotrophic factor (BDNF), lysophosphatidic acid (LPA), growth-derived neurotrophic factor (GDNF)); evaluation of obstetric or perinatal complications. Given that there is no consensus among the different scientific societies on the need for universal screening of thyroid dysfunction during the first trimester and that a universally accepted thyrotropin cut-off point has not been established to initiate treatment with thyroxine in pregnant women, the results of the project will establish a personalised TSH cut-off point that allows therapeutic decision-making. (English) / qualifier
 
point in time: 12 October 2021
Timestamp+2021-10-12T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0

Revision as of 15:50, 12 October 2021

Project Q3155443 in Spain
Language Label Description Also known as
English
Formulation of a personalised fetal and obstetric risk prediction score based on maternal thyroid function.
Project Q3155443 in Spain

    Statements

    0 references
    71,500.0 Euro
    0 references
    143,000.0 Euro
    0 references
    50.0 percent
    0 references
    1 January 2016
    0 references
    31 March 2020
    0 references
    FUNDACION INSTITUTO DE INVESTIGACION EN CIENCIAS DE LA SALUD GERMANS TRIAS I PUJOL
    0 references
    0 references

    41°26'57.66"N, 2°14'53.70"E
    0 references
    08015
    0 references
    Los parámetros de función tiroidea, especialmente en la mujer gestante, están sujetos a una importante variabilidad intra e intersujeto que dificulta su interpretación clínica y la estandarización de criterios diagnósticos y terapéuticos. Objetivo: Generar un score personalizado y predictivo de complicaciones obstétrico-perinatales y de la concentración de biomarcadores de neurodesarrollo fetal basado en la determinación de TSH materna de primer trimestre corregida por los factores más relevantes que determinan la variabilidad de este parámetro. Metodología: a): a1) Estudio de TSH en primer trimestre a partir de un muestreo por conglomerados en 400 gestantes y génesis de un nomograma mediante análisis de regresión múltiple.; a2) Análisis de la validez interna/externa en la determinación de T4 libre durante la gestación. b) medición en sangre de cordón fetal de biomarcadores de neurodesarrollo (brain-derived neurotrophic factor (BDNF), ácido lisofosfatídico (LPA), growth-derived neurotrophic factor (GDNF)); c) evaluación de complicaciones obstétricas y/o perinatales. Dado que no existe un consenso entre las diferentes sociedades científicas sobre la necesidad de cribado universal de la disfunción tiroidea durante el primer trimestre y que no se ha establecido un punto de corte de tirotropina TSH universalmente aceptado para iniciar el tratamiento con tiroxina en gestantes, los resultados del proyecto permitirán establecer un punto de corte personalizado de TSH que permita la toma de decisión terapéutica. (Spanish)
    0 references
    Thyroid function parameters, especially in pregnant women, are subject to significant intra- and intersubjective variability that hinders their clinical interpretation and standardisation of diagnostic and therapeutic criteria. Objective: Generate a personalised and predictive score of obstetric-perinatal complications and concentration of fetal neurodevelopment biomarkers based on the determination of maternal first trimester TSH corrected by the most relevant factors that determine the variability of this parameter. Methodology: (a): a1) TSH study in the first trimester based on cluster sampling in 400 pregnant women and genesis of a nomogram using multiple regression analysis; analysis of internal/external validity in the determination of free T4 during gestation. b) Fetal cord blood measurement of neurodevelopment biomarkers (brain-derived neurotrophic factor (BDNF), lysophosphatidic acid (LPA), growth-derived neurotrophic factor (GDNF)); evaluation of obstetric or perinatal complications. Given that there is no consensus among the different scientific societies on the need for universal screening of thyroid dysfunction during the first trimester and that a universally accepted thyrotropin cut-off point has not been established to initiate treatment with thyroxine in pregnant women, the results of the project will establish a personalised TSH cut-off point that allows therapeutic decision-making. (English)
    12 October 2021
    0 references
    Badalona
    0 references

    Identifiers

    PI15_02192
    0 references